On January 5, 2026, GE HealthCare received notice of an unsolicited mini-tender offer from Potemkin Limited to purchase up to 100,000 shares of its common stock at a price approximately 35% below the most recent closing price. GE HealthCare’s board of directors unanimously concluded that the offer poses material risks to shareholders, including the absence of customary proxy rights, limited regulatory oversight, and potential value erosion. The company has advised investors to reject the offer and has filed a detailed regulatory response, underlining its commitment to protecting shareholder interests and preserving the intrinsic value of its healthcare technology business.

In a strategic collaboration announced at CES 2026, GE HealthCare and NXP Semiconductors will showcase two proof-of-concept products that embed secure, low-latency edge AI into operating room and neonatal intensive care workflows. The first concept enables hands-free, voice-command control of anesthesia delivery systems to reduce cognitive load and alarm fatigue among anesthesiologists. The second concept employs on-device intelligence to monitor infants’ vital states—detecting crying, rest periods, and unsafe positions—with all image processing performed locally to ensure data privacy. Underpinned by GE HealthCare’s Responsible AI principles and NXP’s neural processing units, these initiatives aim to strengthen GE HealthCare’s digital solutions portfolio and open new avenues for recurring software and services revenue.